Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1002/path.4775

http://scihub22266oqcxt.onion/10.1002/path.4775
suck pdf from google scholar
C5071153!5071153 !27477320
unlimited free pdf from europmc27477320
    free
PDF from PMC    free
html from PMC    free

Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27477320 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215

suck abstract from ncbi


Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27477320 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117
pmid27477320
      J+Pathol 2016 ; 240 (3 ): 282-290
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • NTRK3 kinase fusions in Spitz tumours #MMPMID27477320
  • Yeh I ; Tee MK ; Botton T ; Shain AH ; Sparatta AJ ; Gagnon A ; Vemula SS ; Garrido MC ; Nakamaru K ; Isoyama T ; McCalmont TH ; LeBoit PE ; Bastian BC
  • J Pathol 2016[Nov]; 240 (3 ): 282-290 PMID27477320 show ga
  • Oncogenic fusions in TRK family receptor tyrosine kinases have been identified in several cancers and can serve as therapeutic targets. We identified ETV6-NTRK3, MYO5A-NTRK3 and MYH9-NTRK3 fusions in Spitz tumours, and demonstrated that NTRK3 fusions constitutively activate the mitogen-activated protein kinase, phosphoinositide 3-kinase and phospholipase C?1 pathways in melanocytes. This signalling was inhibited by DS-6051a, a small-molecule inhibitor of NTRK1/2/3 and ROS1. NTRK3 fusions expand the range of oncogenic kinase fusions in melanocytic neoplasms and offer targets for a small subset of melanomas for which no targeted options currently exist. Copyright © 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • |Adolescent [MESH]
  • |Adult [MESH]
  • |Aged [MESH]
  • |Child [MESH]
  • |Child, Preschool [MESH]
  • |Comparative Genomic Hybridization [MESH]
  • |Discoidin Domain Receptor 2/*genetics/metabolism [MESH]
  • |ETS Translocation Variant 6 Protein [MESH]
  • |Female [MESH]
  • |Humans [MESH]
  • |Male [MESH]
  • |Melanoma/enzymology/genetics/pathology [MESH]
  • |Mitogen-Activated Protein Kinases/genetics/metabolism [MESH]
  • |Molecular Motor Proteins/*genetics/metabolism [MESH]
  • |Myosin Heavy Chains/*genetics/metabolism [MESH]
  • |Myosin Type V/*genetics/metabolism [MESH]
  • |Nevus, Epithelioid and Spindle Cell/*enzymology/genetics/pathology [MESH]
  • |Oncogene Fusion [MESH]
  • |Phosphatidylinositol 3-Kinases/genetics/metabolism [MESH]
  • |Proto-Oncogene Proteins c-ets/*genetics/metabolism [MESH]
  • |Repressor Proteins/*genetics/metabolism [MESH]
  • |Sequence Analysis, DNA [MESH]
  • |Sequence Analysis, RNA [MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box